The Translational Bridge for Target Validation
A biologic’s interaction with its target is governed by complex molecular mechanics that do not always translate predictably across species. Preclinical models provide safety data, but verification of the therapeutic’s binding profile in human tissue is the definitive measure of clinical relevance. This is especially true for gene therapies, where vector-cell surface interactions can be species-specific. For example, research into engineered AAV9 vectors demonstrates that modifications to glycan binding can produce significant differences in tissue avidity between preclinical models and NHPs (PMID: 39001819). This finding reinforces the need for direct evaluation in primate tissues to accurately forecast human biodistribution and target engagement.
Our cross-reactivity platform provides the necessary data to bridge this translational gap. We utilize a systematic approach to evaluate your biologic against a full panel of FDA- and ICH-recommended tissues.
-
Reagent Qualification: Initial optimization and titration of the biologic to establish ideal staining conditions and confirm specificity on control tissues.
-
Parallel Screening: Simultaneous evaluation on comprehensive panels of human and NHP tissues, processed under identical GxP conditions for direct comparability.
-
Pathologist Review: Interpretation of binding patterns by board-certified pathologists to distinguish specific on-target engagement from non-specific or non-target binding.
This systematic process generates the specific binding data required for confident program decisions.
